Skip to main content

Table 1 Baseline clinical information of the investigated glioma patients

From: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Variable

Number of cases

Gender

 Male

14

 Female

16

WHO grade

 I–II

10

 III

10

 IV

10

Age (years)

 < 40

7

 40–49

10

 50–59

9

 60–69

2

 ≥ 70

2

Resection type

 Total

24

 Partial

6

 Survival status

 Alive

17

 Dead

13

Pathologic diagnosis

 Astrocytoma

7

 Oligodendroglioma/oligoastrocytoma

3

 Anaplastic astrocytoma

5

 Anaplastic oligodendroglioma/mixed

5

 Glioblastoma

10

  1. WHO World Health Organization